Table 1.

Chemosensitization of MCF-7 breast cancer cells to doxorubicin

Treatment (plus doxorubicin)*IC50 (nmol/L)Fold sensitization
-144 ± 36
siRNA plus C9-P55 ± 42.6
siRNA plus C9D-P53 ± 12.7
siRNA plus C9LZ-P35 ± 204.2
siRNA plus LipofectAMINE 200027 ± 65.3
siRNA plus C9133 ± 51.1

NOTE: Treatment was done as described in the legend to Fig. 6.

  • Doxorubicin concentrations were used in the range of 1 nmol/L to 100 μmol/L, and cell viability was determined in cell proliferation assays.

  • IC50: concentration at which cell viability/proliferation was inhibited by 50%. Data are reported as mean ± SD, n = 3.

  • Fold sensitization was determined as the ratio of IC50 values of doxorubicin after control treatment and treatment with the various complexes.